Sponsors of PSCK9 inhibitors and other novel lipid-altering agents will have as much, if not more, on the line as Merck & Co. Inc. when an FDA advisory committee reviews data from the IMPROVE-IT cardiovascular outcomes trial of the company's Zetia (ezetimibe) on Dec. 14.
If the IMPROVE-IT data can withstand FDA's clinical and statistical scrutiny, the end result could be a CV benefit claim...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?